Qamar Biosystems delivers clinically validated amnion membrane allografts to hospitals and wound-care programs across Saudi Arabia — through a regulatory-first model built on U.S. tissue-science partnerships, verified cold-chain logistics, and clinician training.
Saudi Arabia has one of the highest diabetes prevalence rates in the world. A significant share of diabetic foot ulcers progress to infection, hospitalization, and lower-limb amputation — with five-year survival after major amputation often below 50%.
Standard wound care alone frequently fails in high-risk patients whose healing biology is compromised. Closing this gap requires advanced biologic therapies, deployed early and systematically.
Figures drawn from International Diabetes Federation estimates and peer-reviewed regional epidemiology.
Amnion membrane allografts are sterile human tissue products derived from ethically donated, rigorously screened placental tissue recovered after healthy, planned cesarean births. The amnion provides a collagen-rich extracellular matrix that supports the body's own healing cascade — precisely where diabetic wound biology has stalled.
A non-immunogenic profile with a long clinical history and low reported adverse-event rates.
Natural reservoir of growth factors, cytokines, hyaluronic acid, and antimicrobial peptides that support tissue repair.
Guides cellular migration and re-epithelialization, moderating inflammation and excessive scarring.
Recovered, screened, and processed by FDA-registered U.S. tissue establishments under cGTP and AATB-aligned standards.
Randomized controlled trials, multicenter prospective studies, and multiple meta-analyses consistently support amnion membrane grafts as an adjunct to standard care in chronic diabetic foot ulcers.
Meta-analysis of 11 randomized controlled trials found amniotic membrane products increase the probability of complete DFU closure two- to four-fold versus standard care alone.
Across RCTs and prospective series, 70–90% of treated ulcers achieved full closure within 6–12 weeks — with faster healing than standard care in head-to-head trials.
Across trials and longitudinal studies, amnion grafts show very low adverse-event rates and no consistent pattern of graft-related complications.
Faster closure means fewer infections, fewer hospitalizations, and fewer preventable amputations. Our clinical team provides full study bibliographies and evidence summaries to physicians, health clusters, and institutional review committees.
Request the evidence dossier →Qamar Biosystems supplies allografts through its partnership with Surgenex — ensuring every graft delivered in the Kingdom meets American processing, screening, and traceability standards.
A U.S. biotechnology firm specializing in placental tissue allografts since 2014, processing amnion-derived grafts on-site in ISO-classified cleanroom facilities in Scottsdale, Arizona.
This partnership gives Qamar Biosystems dedicated, scalable access to clinical-grade amnion allografts — with the quality documentation required for SFDA registration and institutional procurement in the Kingdom.
Our operating model is designed around the Kingdom's institutions, standards, and Vision 2030 health transformation priorities.
Product registration and import authorization pursued through the Saudi Food & Drug Authority and Ministry of Health before commercial distribution — full technical dossiers, sterility data, and traceability documentation included.
Temperature-controlled transport and storage designed to protect graft integrity from U.S. processor to Saudi operating room, with monitoring and documented handling protocols.
Application training, protocol guidance, and literature support for vascular surgery, endocrinology, podiatry, and wound-care teams — so adoption is confident and consistent.
Serialized, traceable grafts and structured outcome tracking that align with national digital-health infrastructure and value-based care objectives.
Hospitals, health clusters, wound-care programs, and distribution partners across Saudi Arabia and the GCC — we welcome the conversation.